NA-Selank Amidate — Research, Dosing & Price Guide

N-Acetyl Selank Amidate is an enhanced version of Selank, a synthetic heptapeptide analog of the naturally occurring immunomodulatory peptide tuftsin. The N-acetyl and amide modifications significantly improve its stability, half-life, and blood-brain barrier penetration. It is primarily used as an anxiolytic nootropic, providing calm focus without sedation, and has immunomodulatory properties that distinguish it from conventional anxiolytic drugs.

NA-Selank Amidate modulates multiple neurotransmitter systems simultaneously. Its primary anxiolytic mechanism involves allosteric modulation of GABA-A receptors, enhancing GABAergic inhibitory tone in the amygdala and prefrontal cortex without the sedation or dependence associated with benzodiazepines. It also stabilizes enkephalin levels by inhibiting enkephalinase, prolonging the activity of these endogenous opioid peptides involved in stress resilience and mood regulation. Additionally, it influences serotonin metabolism, modulating the balance of 5-HT and its metabolites in the hippocampus and frontal cortex. The immunomodulatory effects derive from its tuftsin backbone — it stimulates IL-6 production, modulates T-helper cell balance, and enhances phagocytic activity. The N-acetyl and amide modifications extend the peptide's half-life from minutes to over an hour and improve CNS penetration.

• Seredenin et al. (2008) in Bulletin of Experimental Biology and Medicine showed Selank had anxiolytic effects comparable to benzodiazepines in the elevated plus maze without motor impairment or sedation
• Russian clinical studies demonstrated Selank's efficacy for generalized anxiety disorder, leading to its approval in Russia as an anxiolytic medication
• Research in Molecular Genetics, Microbiology and Virology (2009) showed Selank modulated expression of 36 genes related to immune and inflammatory pathways
• Kozlovskii and Danchev (2003) demonstrated Selank enhanced memory consolidation and attention in rodent models
• Studies showed Selank stabilized blood enkephalin levels in stressed animals, explaining its anti-anxiety mechanism (Bulletin of Experimental Biology and Medicine, 2006)
• Preclinical research demonstrated antiviral properties against influenza through immunomodulatory mechanisms

• Intranasal: 200–600 mcg per nostril, 1–3 times daily
• Subcutaneous: 250–750 mcg once or twice daily
• Start with 200 mcg intranasally to assess response
• Can be used situationally for acute anxiety or daily for sustained anxiolytic effects
• Cycle: 2–4 weeks on, 1–2 weeks off, though some use continuously for longer periods
• Best stacked with NA-Semax Amidate for balanced stimulation and calm
• Effects onset within 10–20 minutes intranasally

Known Side Effects

• Nasal irritation — mild dryness or tingling when used intranasally, usually diminishes with continued use
• Fatigue — some users report mild drowsiness, particularly at higher doses or when combined with other GABAergic substances
• Headache — infrequently reported, generally mild and self-resolving
• Emotional blunting — rarely, some users report reduced emotional intensity at higher doses, suggesting over-modulation of limbic activity
• No reported dependence, withdrawal, or tolerance development — a significant advantage over benzodiazepines

Safety Profile

Selank has a well-established safety record from its clinical use in Russia since the early 2000s, prescribed for anxiety, neurasthenia, and cognitive impairment. It does not produce physical dependence, tolerance, or withdrawal symptoms — key advantages over benzodiazepines. There is no evidence of sedation-related cognitive impairment at standard doses. The immunomodulatory effects are generally beneficial but individuals with autoimmune conditions should exercise caution. No dangerous drug interactions have been identified, though combining with other GABAergic substances (alcohol, benzodiazepines, gabapentin) may produce additive sedation. The NA-Selank Amidate form has not undergone independent clinical trials but is pharmacologically similar to the approved parent compound with enhanced stability.

Within 10–20 minutes (intranasal): A subtle but noticeable reduction in background anxiety and mental tension. Users describe a 'calm clarity' without sedation or cognitive dulling. Days 1–3: Anxiolytic effects are consistent and reliable with each dose. Social interactions feel easier, stress tolerance improves, and rumination decreases. Week 1–2: Cumulative benefits emerge — improved stress resilience, better emotional regulation, and enhanced ability to focus under pressure. Sleep quality often improves as evening anxiety decreases. Weeks 3–4: Peak anxiolytic and immunomodulatory effects. Users report a stable, calm baseline mood with improved cognitive performance. After cessation, there is no withdrawal — effects fade gradually over 3–7 days.

Prices sourced from peptides.gg marketplace. Prices may vary.